SCHEMBL8772465

SCHEMBL8772465

CC(=O)c1ccc2c(c1)-c1c(cc(O)c3cc(C(F)(F)F)ccc13)C2(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 3/20 0.37
AKR1C2 P52895 3/20 0.37
SLC6A2 P23975 1/20 0.36
P2RY14 Q15391 1/20 0.36
KIF11 P52732 1/20 0.36
PDK2 Q15119 1/20 0.35
BCL2L1 Q07817 1/20 0.34
PLD2 O14939 1/20 0.34
PLD1 Q13393 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
PTGS2 P35354 1/20 0.33
MAOB P27338 4/20 0.33
TOP2A P11388 1/20 0.33
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
MEN1 O00255 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16713281 0.91 SLC6A2 (0.44) SLC6A2P2RY14PDK2BCL2L1PTGS2
SCHEMBL6113895 0.88 PDK2 (0.43) KIF11PDK2
SCHEMBL1960938 0.85 MEN1 (0.44) RXFP1MEN1CYP3A4CYP2D6CYP2C19
SCHEMBL10323482 0.84 SLC6A2 (0.35) SLC6A2P2RY14KIF11PTGS2TOP2A
SCHEMBL18754293 0.83 P2RX1 (0.49) RXFP1MEN1KMT2AMAPT
SCHEMBL16742523 0.82 PDK2 (0.41) SLC6A2P2RY14KIF11PDK2RXRA
SCHEMBL6113613 0.80 PTGS2 (0.33) PTGS2
SCHEMBL16713285 0.75 KDM4E (0.36) PDK2PTGS2RXRARXRBMAPT
SCHEMBL16713283 0.74 PDK2 (0.41) PDK2PTGS2RXRARXRBKMT2A
SCHEMBL16713268 0.74 CNR2 (0.37) PTGS2RXRARXRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309455-B2 Indeno-fused ring compounds TRANSITIONS OPTICAL, INC. (US) 2016-04-12 US disclosed
US-20140166948-A1 INDENO-FUSED RING COMPOUNDS TRANSITIONS OPTICAL LIMITED (IE) 2014-06-19 US disclosed
US-20120126185-A1 INDENO-FUSED RING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120126185-A1 INDENO-FUSED RING COMPOUNDS CRY2, SQOR, INTS6 AKR1C3 463/4885AKR1C2 583/4885SLC6A2 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.